graft-versus-host disease

[IN8bio, Inc.] IN8bio, Inc. announced completion of dosing of the first patient cohort in a Phase I clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant.

[Nature Communications] Scientists showed that human T cells engineered to express an mLPA-specific TCR, targeted diverse CD1c-expressing leukemia blasts in vitro and significantly delayed the progression of three models of leukemia xenograft in NSG mice, an effect that was boosted by mLPA-cellular immunization.

[Stem Cell Research] Scientists generated an induced pluripotent stem cells (iPSC) line from bone marrow-MSCs employing a non-integrating episomal vector. The generated iPSCs expressed pluripotency markers, showed a normal karyotype, and exhibited the potential for in vitro differentiation into three germ layers.

[Bone Marrow Transplantation] The authors evaluated the outcome of recipients of alternative donor allogeneic stem cell transplantation for T-cell lymphoma.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.

[Journal of Clinical Oncology] In this single-center, Phase I trial, researchers administered anti-CD7 chimeric antigen receptor (CAR) T cells, manufactured from either previous stem-cell transplantation donors or new donors, to patients with relapsed or refractory T-cell acute lymphoblastic leukemia, in single infusions at doses of 5 × 105 or 1 × 106 cells per kilogram of body weight.